Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jason Kim

Urogynecology and Reconstructive Pelvic Surgery Stony Brook, NY Medical Doctor

NPI 1275707846 CMS profile 1225907

Department Of Urology Hsc 9, Stony Brook University Medical Center, Stony Brook, NY 11794

Open in the dashboard

General payments

$346,006

482 records reported · program years 2019–2025

Research payments

$2,806

Paid to them · 4 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$192,861 paid to institutions, not to them · program years 2022–2025

Through program year 2025, Jason Kim of Stony Brook, NY is reported in the CMS Open Payments database as having received $346,006 across 482 general payments and $2,806 in research payments paid to them. Separately, studies naming them as principal investigator received $192,861 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $134,975 97
2024 General $82,621 112
2024 Research $355 1
2023 General $89,146 131
2022 General $28,825 91
2022 Research $2,096 2
2021 General $8,753 25
2021 Research $355 1
2020 General $1,162 12
2019 General $526 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jason Kim
  • Urogynecology and Reconstructive Pelvic Surgery median
  • Middle half of Urogynecology and Reconstructive Pelvic Surgery
  • National median

In program year 2025, general payments to Jason Kim were reported at $134,975. Among 149 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $779 and the middle half received between $301 and $2,705.

Show as a table
Year Jason Kim Urogynecology and Reconstructive Pelvic Surgery median Middle half National median
2019 $526 $799 $319–$2,013 $163
2020 $1,162 $384 $158–$1,360 $114
2021 $8,753 $641 $247–$2,515 $132
2022 $28,825 $843 $347–$2,794 $149
2023 $89,146 $819 $308–$2,302 $160
2024 $82,621 $882 $306–$2,459 $164
2025 $134,975 $779 $301–$2,705 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Valencia Technologies Corporation $268,528 98 payments
  2. AbbVie, Inc. $45,648 97 payments
  3. Medtronic, Inc. $8,286 127 payments
  4. Boston Scientific Corporation $6,992 23 payments
  5. Allergan Inc. $6,406 16 payments
  6. Caldera Medical, Inc $5,424 14 payments
  7. Axonics Modulation Technologies, Inc. $1,690 36 payments
  8. Medtronic USA, Inc. $874 6 payments
  9. 180 Medical, Inc. $394 19 payments
  10. Coloplast Corp $360 6 payments
  11. Other $1,406 40 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $244,257 34 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $45,225 15 payments
  3. Travel and Lodging $39,101 72 payments
  4. Food and Beverage $17,216 356 payments
  5. Education $122 3 payments
  6. Gift $86 2 payments
Products named General payments · program years 2019–2025
  1. eCoin Device Kit $268,528 98 payments
  2. BOTOX Urology $48,016 52 payments
  3. INTERSTIM $7,073 120 payments
  4. Desara $5,424 14 payments
  5. BOTOX Botox Therapeutic $3,524 38 payments
  6. Axonics $1,156 28 payments
  7. Bulkamid $1,079 10 payments
  8. Axonics r-SNM System $467 6 payments
  9. ALTAVIVA $464 3 payments
  10. BOTOX Hyperhydrosis $367 19 payments
  11. Other $2,693 64 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $2,806 4 payments

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

470

Median for Urology: 1,053

Drug cost

$124,610

Median for Urology: $101,464

Branded share of claims

56%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 66 $48,140
Myrbetriq Mirabegron Brand 54 $38,999
Mirabegron Er Mirabegron Brand 15 $13,907
Estradiol Generic 44 $7,266
Methenamine Hippurate Generic 57 $7,076
Yuvafem Estradiol Brand 32 $4,306
Tamsulosin Hcl Generic 74 $1,401
Tadalafil Generic 15 $1,204
Potassium Citrate Er Potassium Citrate Brand 15 $930
Oxybutynin Chloride Er Oxybutynin Chloride Brand 44 $628

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 82 billing codes

Paid by Medicare

$487,420

Of which drugs: $53,571

Medicare patients

986

Average age 74

Services billed

15,086

772 women, 214 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Diabetes 38%
Ischemic heart disease 38%
Depression 35%
Chronic kidney disease 28%
Osteoporosis 27%
Atrial fibrillation 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 57 10,800 $53,567

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $17,299
$17,299 — 10,800
GEMTESA
  • Sumitomo Pharma America, Inc. $45
$45 66 —
Veozah
  • Astellas Pharma US Inc $24
$24 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

486 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urogynecology and Reconstructive Pelvic Surgery in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record